... risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. American Journal of Human Genetics. 2003;72(5):1117-1130 [213] King MC ...
... nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.Cancer Epidemiology, Biomarkers & Prevention21 (8):1362-1370. doi:10.1158/1055-9965.epi-12 ...
... growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers . Breast Cancer Res . 2009 , 11 , R76 . 31. Slattery , M.L .; Samowitz , W .; Curtin , K .; Ma , K.N .; Hoffman , M .; Caan , B .; Neuhausen , S.
... nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers . Cancer Epidemiol . Biomark . Prev . 2012 , 21 , 1362–1370 . [ CrossRef ] 79 ...
... cancer risk . Breast Cancer Res 2009 ; 11 ( Suppl . 3 ) : S3 . PMID : 20030878 . [ 26 ] Hamajima N , Hirose K ... BRCA1 and BRCA2 among Ashkenazi Jews . N Engl J Med 1997 ; 336 ( 20 ) : 1401–8 . [ 39 ] Couch FJ , Nathanson KL ...
- The data gathered can be used to solve a wide range of problems - for basic science and applied science
Introducing the definitive gynecologic oncology reference and surgical atlas—in one essential text Gynecologic Oncology: Clinical Practice and Surgical Atlas brings together a skill-sharpening reference and full-color atlas to deliver an ...
This book offers a broad-ranging assessment of current efforts of the molecular, cellular, hormonal, nutritional and lifestyle strategies being tested and applied by biogerontologists in the search for effective means of intervention, ...
This book is aimed at a very spe tomicrographs myself, while Dr. Curt Littler cific readership-first-year residents in pathol has provided a number of new illustrations.
In this book, clinicians and basic scientists from USA, India, and other countries discuss the rationales and clinical experiences with targeted approaches to treat, prevent, or manage cancer.